Semaglutide
- Generic Name
- Semaglutide
- Brand Names
- Ozempic, Rybelsus, Wegovy
- Drug Type
- Small Molecule
- Chemical Formula
- C187H291N45O59
- CAS Number
- 910463-68-2
- Unique Ingredient Identifier
- 53AXN4NNHX
- Background
Semaglutide is a glucagon-like peptide 1 (GLP-1) analog used to manage type 2 diabetes along with lifestyle changes, such as dietary restrictions and increased physical activity. Other members of this drug class include Exenatide and Liraglutide. Semaglutide was developed by Novo Nordisk and approved by the FDA for subcutaneous injection in December 2017. Th...
- Indication
Semaglutide is indicated to improve glycemic control in adults diagnosed with type 2 diabetes mellitus, and is used as an adjunct to diet and exercise. However, semaglutide is not a suitable first-line drug for diabetes that has not been controlled by diet and exercise. In addition, it has not been studied in patients with pancreatitis. Semaglutide is not in...
- Associated Conditions
- BMI >27 kg/m2, Cardiovascular Events, Obesity, Type 2 Diabetes Mellitus
- Associated Therapies
- Chronic Weight Management therapy
Efficacy, Safety, and Tolerability of Once Daily Oral Administration of AZD5004 Versus Placebo for 26 Weeks in Adults With Type 2 Diabetes Mellitus.
- Conditions
- Interventions
- First Posted Date
- 2024-08-30
- Last Posted Date
- 2024-11-20
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 384
- Registration Number
- NCT06579105
- Locations
- 🇬🇧
Research Site, Dundee, United Kingdom
STEP TEENS Weight Maintenance: A Research Study on How Well Semaglutide Helps Teenagers With Excess Body Weight to Lose Weight and Maintain Weight Loss
- First Posted Date
- 2024-08-26
- Last Posted Date
- 2024-12-20
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 500
- Registration Number
- NCT06571383
- Locations
- 🇨🇦
Maison de Sante Prevention, Montreal, Quebec, Canada
🇵🇱Górnośląskie Centrum Zdrowia Dziecka Im. Św. Jana Pawla II Samodzielny Publiczny Szpital Kliniczny Nr 6 SUM w Katowicach, Katowice, Poland
🇺🇸Neighborhood Healthcare, Escondido, California, United States
Effect of Oral Semaglutide on Epicardial and Pericoronary Adipose Tissues in Type 2 Diabetes After Myocardial Infarction
- Conditions
- Interventions
- First Posted Date
- 2024-08-16
- Last Posted Date
- 2024-08-26
- Lead Sponsor
- University of Sao Paulo General Hospital
- Target Recruit Count
- 88
- Registration Number
- NCT06557811
- Locations
- 🇧🇷
ARO (Academic Research Organization), São Paulo, SP, Brazil
Mechanisms of Semaglutide Therapy in Heart Failure Patients
- First Posted Date
- 2024-08-07
- Last Posted Date
- 2024-08-07
- Lead Sponsor
- University Medical Centre Ljubljana
- Target Recruit Count
- 10
- Registration Number
- NCT06541509
- Locations
- 🇸🇮
University Medical Center Ljubljana, Ljubljana, Slovenia
🇺🇸Greenstone Biosciences, Palo Alto, California, United States
🇺🇸Stanford Cardiovascular Institute, Stanford, California, United States
A Research Study to See How Much CagriSema (1.0 mg Once Weekly) Lowers Blood Sugar and Body Weight Compared to Tirzepatide (5 mg Once Weekly) in People With Type 2 Diabetes Treated With Metformin, SGLT2 Inhibitor or Both
- Conditions
- Interventions
- First Posted Date
- 2024-08-02
- Last Posted Date
- 2024-11-22
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 1000
- Registration Number
- NCT06534411
- Locations
- 🇺🇸
Cahaba Research, Pelham, Alabama, United States
🇺🇸Velocity Clinical Research-Phoenix, Phoenix, Arizona, United States
🇺🇸AES Tucson DRS, Tucson, Arizona, United States
Holding vs. Continuing Incretin-based Therapies Before Upper Endoscopy
- Conditions
- Interventions
- First Posted Date
- 2024-08-01
- Last Posted Date
- 2024-08-14
- Lead Sponsor
- The Cleveland Clinic
- Target Recruit Count
- 120
- Registration Number
- NCT06533527
- Locations
- 🇺🇸
Cleveland Clinic, Weston, Florida, United States
Real World Effectiveness of Oral Semaglutide in Thailand Participants With Type 2 Diabetes
- First Posted Date
- 2024-07-18
- Last Posted Date
- 2024-07-18
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 209
- Registration Number
- NCT06507475
Semaglutide for Metabolic Intervention and Adipose Loss to Treat Atrial Fibrillation
- Conditions
- Interventions
- First Posted Date
- 2024-07-15
- Last Posted Date
- 2024-10-07
- Lead Sponsor
- University of Chicago
- Target Recruit Count
- 200
- Registration Number
- NCT06499857
- Locations
- 🇺🇸
University of Chicago, Chicago, Illinois, United States
🇺🇸The University of Arizona College of Medicine- Phoenix, Phoenix, Arizona, United States
The Effects of Semaglutide vs Testosterone Replacement Therapy on Functional Hypogonadism and Sperm Quality in Men With Type 2 Diabetes Mellitus and Obesity
- Conditions
- Interventions
- First Posted Date
- 2024-07-08
- Last Posted Date
- 2024-07-08
- Lead Sponsor
- University Medical Centre Ljubljana
- Target Recruit Count
- 25
- Registration Number
- NCT06489457
- Locations
- 🇸🇮
University Medical Centre Ljubljana, Ljubljana, Slovenia
A Research Study to Understand How People With Type 2 Diabetes Take Ozempic® and if the Ozempic®App Helps Them Stay on This Treatment
- First Posted Date
- 2024-06-27
- Last Posted Date
- 2024-06-27
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 304
- Registration Number
- NCT06478550
- Locations
- 🇬🇷
University Hospital of Athens ATTIKON, Haidari-Athens, Attica, Greece
🇬🇷General Hospital Of Thessaloniki Papageorgiou, Thessaloniki, Nea Efkarpia, Greece
🇬🇷"Laiko" General Hospital of Athens, Goudi/Athens, Greece
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.